Chen, Y., Gopalakrishnan, S. K., Ooi, M., Sultana, R., Lim, L. H., Grigoropoulos, N., . . . MEDICINE. (2021). A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). SPRINGERNATURE.
استشهاد بنمط شيكاغوChen, Yunxin, et al. A Phase 2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone As Frontline Treatment for Transplant-eligible MM With High-risk Features (SGH-MM1). SPRINGERNATURE, 2021.
MLA استشهادChen, Yunxin, et al. A Phase 2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone As Frontline Treatment for Transplant-eligible MM With High-risk Features (SGH-MM1). SPRINGERNATURE, 2021.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.